{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:17:11Z","timestamp":1791173831389,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s11060-011-0652-z","type":"journal-article","created":{"date-parts":[[2011,6,30]],"date-time":"2011-06-30T09:19:04Z","timestamp":1309425544000},"page":"155-160","source":"Crossref","is-referenced-by-count":34,"title":["Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status"],"prefix":"10.1007","volume":"106","author":[{"given":"Keishi","family":"Makino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku-ichiro","family":"Hide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ichi","family":"Kuratsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,7,1]]},"reference":[{"key":"652_CR1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1023\/A:1006258619757","volume":"43","author":"LM DeAngelis","year":"1999","unstructured":"DeAngelis LM (1999) Primary CNS lymphoma: treatment with combined chemotherapy and radiotherapy. J Neurooncol 43:249\u2013257","journal-title":"J Neurooncol"},{"key":"652_CR2","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1023\/A:1008376412784","volume":"11","author":"AJ Ferreri","year":"2000","unstructured":"Ferreri AJ, Reni M, Villa E (2000) Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials. Ann Oncol 11:927\u2013937","journal-title":"Ann Oncol"},{"key":"652_CR3","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1200\/JCO.2000.18.17.3144","volume":"18","author":"LE Abrey","year":"2000","unstructured":"Abrey LE, Yahalom J, DeAngelis LM (2000) Treatment for primary CNS lymphoma: the next step. J Clin Oncol 18:3144\u20133150","journal-title":"J Clin Oncol"},{"key":"652_CR4","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.2003.03.036","volume":"21","author":"T Batchelor","year":"2003","unstructured":"Batchelor T, Carson K, O\u2019Neill A, Grossman SA, Alavi J, New P, Hochberg F, Priet R (2003) Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 21:1044\u20131049","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"652_CR5","doi-asserted-by":"crossref","first-page":"B113","DOI":"10.1007\/PL00022772","volume":"80","author":"M Reni","year":"2001","unstructured":"Reni M, Ferreri AJ (2001) Therapeutic management of refractory or relapsed primary central nervous system lymphomas. Ann Hematol 80(Suppl 3):B113\u2013B117","journal-title":"Ann Hematol"},{"key":"652_CR6","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/sj.bjc.6690083","volume":"79","author":"M Reni","year":"1999","unstructured":"Reni M, Ferreri AJ, Villa E (1999) Second-line treatment for primary central nervous system lymphoma. Br J Cancer 79:530\u2013534","journal-title":"Br J Cancer"},{"key":"652_CR7","doi-asserted-by":"crossref","unstructured":"Reni M, Ferreri AJ (2004) Is withdrawal of consolidation radiotherapy an evidence-based strategy in primary central nervous system lymphomas? J Clin Oncol 22:1165\u20131167; author reply 1167\u20131168","DOI":"10.1200\/JCO.2004.99.259"},{"key":"652_CR8","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1200\/JCO.2003.01.135","volume":"21","author":"AJ Ferreri","year":"2003","unstructured":"Ferreri AJ, Abrey LE, Blay JY, Borisch B, Hochman J, Neuwelt EA, Yahalom J, Zucca E, Cavalli F, Armitage J, Batchelor T (2003) Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol 21:2407\u20132414","journal-title":"J Clin Oncol"},{"key":"652_CR9","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1212\/WNL.58.10.1573","volume":"58","author":"U Herrlinger","year":"2002","unstructured":"Herrlinger U, Kuker W, Platten M, Dichgans J, Weller M (2002) First-line therapy with temozolomide induces regression of primary CNS lymphoma. Neurology 58:1573\u20131574","journal-title":"Neurology"},{"key":"652_CR10","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.ejca.2004.03.008","volume":"40","author":"M Reni","year":"2004","unstructured":"Reni M, Mason W, Zaja F, Perry J, Franceschi E, Bernardi D, Dell\u2019Oro S, Stelitano C, Candela M, Abbadessa A, Pace A, Bordonaro R, Latte G, Villa E, Ferreri AJ (2004) Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 40:1682\u20131688","journal-title":"Eur J Cancer"},{"key":"652_CR11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2176\/nmc.47.229","volume":"47","author":"K Makino","year":"2007","unstructured":"Makino K, Nakamura H, Kudo M, Takeshima H, Kuratsu J (2007) Complete response to temozolomide treatment in an elderly patient with recurrent primary central nervous system lymphoma\u2014case report. Neurol Med Chir (Tokyo) 47:229\u2013232","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"652_CR12","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/jnci\/92.7.575","volume":"92","author":"M Reni","year":"2000","unstructured":"Reni M, Ferreri AJ, Landoni C, Villa E (2000) Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. J Natl Cancer Inst 92:575\u2013576","journal-title":"J Natl Cancer Inst"},{"key":"652_CR13","first-page":"4121","volume":"24","author":"HM Strik","year":"2004","unstructured":"Strik HM, Spreer A, Nagel H, Jacob S, Jung W, Kitze B, Bahr M (2004) Clinical response following adjuvant temozolomide in a patient with primary cerebral lymphoma. Anticancer Res 24:4121\u20134125","journal-title":"Anticancer Res"},{"key":"652_CR14","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/sj.bjc.6603660","volume":"96","author":"M Reni","year":"2007","unstructured":"Reni M, Zaja F, Mason W, Perry J, Mazza E, Spina M, Bordonaro R, Ilariucci F, Faedi M, Corazzelli G, Manno P, Franceschi E, Pace A, Candela M, Abbadessa A, Stelitano C, Latte G, Ferreri AJ (2007) Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer 96:864\u2013867","journal-title":"Br J Cancer"},{"key":"652_CR15","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997\u20131003","journal-title":"N Engl J Med"},{"key":"652_CR16","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","volume":"23","author":"LE Abrey","year":"2005","unstructured":"Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis LM, Neuwelt EA, O\u2019Neill BP, Thiel E, Shenkier T, Graus F, van den Bent M, Seymour JF, Poortmans P, Armitage JO, Cavalli F (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 23:5034\u20135043","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"652_CR17","doi-asserted-by":"crossref","unstructured":"Kamiryo T, Tada K, Shiraishi S, Shinojima N, Kochi M, Ushio Y (2004) Correlation between promoter hypermethylation of the O6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy. Neurosurgery 54:349\u2013357; discussion 357","DOI":"10.1227\/01.NEU.0000103422.51382.99"},{"key":"652_CR18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1006210703827","volume":"43","author":"N Guha-Thakurta","year":"1999","unstructured":"Guha-Thakurta N, Damek D, Pollack C, Hochberg FH (1999) Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neurooncol 43:259\u2013268","journal-title":"J Neurooncol"},{"key":"652_CR19","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.1158\/1078-0432.CCR-04-0159","volume":"10","author":"SR Plotkin","year":"2004","unstructured":"Plotkin SR, Betensky RA, Hochberg FH, Grossman SA, Lesser GJ, Nabors LB, Chon B, Batchelor TT (2004) Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res Off J Am Assoc Cancer Res 10:5643\u20135646","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"652_CR20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1034\/j.1600-0609.2003.00045.x","volume":"70","author":"E Arellano-Rodrigo","year":"2003","unstructured":"Arellano-Rodrigo E, Lopez-Guillermo A, Bessell EM, Nomdedeu B, Montserrat E, Graus F (2003) Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol 70:219\u2013224","journal-title":"Eur J Haematol"},{"key":"652_CR21","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1212\/01.WNL.0000137050.43114.42","volume":"63","author":"RH Enting","year":"2004","unstructured":"Enting RH, Demopoulos A, DeAngelis LM, Abrey LE (2004) Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63:901\u2013903","journal-title":"Neurology"},{"key":"652_CR22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/cncr.20339","volume":"101","author":"ET Wong","year":"2004","unstructured":"Wong ET, Tishler R, Barron L, Wu JK (2004) Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 101:139\u2013145","journal-title":"Cancer"},{"key":"652_CR23","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/annonc\/mdl070","volume":"17","author":"L Fischer","year":"2006","unstructured":"Fischer L, Thiel E, Klasen HA, Birkmann J, Jahnke K, Martus P, Korfel A (2006) Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol 17:1141\u20131145","journal-title":"Ann Oncol"},{"key":"652_CR24","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1002\/ijc.22124","volume":"119","author":"LC Chu","year":"2006","unstructured":"Chu LC, Eberhart CG, Grossman SA, Herman JG (2006) Epigenetic silencing of multiple genes in primary CNS lymphoma. Int J Cancer 119:2487\u20132491","journal-title":"Int J Cancer"},{"key":"652_CR25","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11060-009-0032-0","volume":"97","author":"D Kurzwelly","year":"2010","unstructured":"Kurzwelly D, Glas M, Roth P, Weimann E, Lohner H, Waha A, Schabet M, Reifenberger G, Weller M, Herrlinger U (2010) Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. J Neurooncol 97:389\u2013392","journal-title":"J Neurooncol"},{"key":"652_CR26","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1532\/IJH97.06087","volume":"84","author":"J Hiraga","year":"2006","unstructured":"Hiraga J, Kinoshita T, Ohno T, Mori N, Ohashi H, Fukami S, Noda A, Ichikawa A, Naoe T (2006) Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma. Int J Hematol 84:248\u2013255","journal-title":"Int J Hematol"},{"key":"652_CR27","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/jnci\/94.1.26","volume":"94","author":"M Esteller","year":"2002","unstructured":"Esteller M, Gaidano G, Goodman SN, Zagonel V, Capello D, Botto B, Rossi D, Gloghini A, Vitolo U, Carbone A, Baylin SB, Herman JG (2002) Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst 94:26\u201332","journal-title":"J Natl Cancer Inst"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-011-0652-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-011-0652-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-011-0652-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T22:03:28Z","timestamp":1686175408000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-011-0652-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["652"],"URL":"https:\/\/doi.org\/10.1007\/s11060-011-0652-z","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,1]]}}}